Korean J Dermatol.
2013 Sep;51(9):743-745.
A Case of Psoriasiform Dermatitis Following Adalimumab Injection for Treatment of Ankylosing Spondylitis
- Affiliations
-
- 1Department of Dermatology, Konkuk University School of Medicine, Seoul, Korea. 20100112@kuh.ac.kr
Abstract
- Adalimumab (Humira(TM)) is the first fully humanized monoclonal TNF-alpha antibody that antagonizes the effects of TNF-alpha. Its use has been found in the treatment of various rheumatologic disorders, namely rheumatoid arthritis, Crohn's disease, and ankylosing spondylitis, as well as for various skin conditions such as psoriasis. As the use of this particular biologic agent is becoming more widespread, cutaneous adverse effects of the drug is now being reported at a steady rate. The authors herein report a case of 32 year-old female who presented with multiple psoriasiform eruptions on her trunk, back and lower extremities. She had a four-year history of ankylosing spondylitis, for which she was started on subcutaneous adalimumab injection monthly, three and a half years prior to her initial visit.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- A Case of Adalimumab-Induced Psoriasiform Dermatitis in an Ankylosing Spondylitis Patient: Unusual Progression after Adalimumab Retreatment
- A Case of Psoriasiform Dermatitis Followed by Tumor Necrosis Factor Inhibitor Treated with Phototherapy
- Palmoplantar Pustulosis Induced by both Adalimumab and Golimumab for Treatment of Ankylosing Spondylitis
- An Atypical Case of Plasmodium vivax Malaria after Initiating Adalimumab Therapy
- Granuloma Annulare Induced by Adalimumab
